(c) Patients with long-term neutropenia and thrombocytopenia may benefit from GM-CSF treatment at a dose of 250 mcg/m2/day (141), but it should not be administered in the first 3 weeks after injection of KYMRIAH (a CD19-CAR-T cell therapy) or before CRS is resolved (142). Here, CSF2 is linked to congenital rubella syndrome.